TBPH FY 2018 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$697M

FY 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$60M+292.4% YoY

Gross Profit

$60M98.8% margin

Operating Income

-$239M-395.5% margin

Net Income

-$216M-357.0% margin

EPS (Diluted)

$-3.99

Cash Flow

Operating Cash Flow

-$113M

Free Cash Flow

-$120M

Stock-Based Comp.

$51M

Balance Sheet

Total Assets

$560M

Total Liabilities

$612M

Stockholders' Equity

-$52M

Cash & Equivalents

$378M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$60M	$15M	+292.4%
Gross Profit	$60M	$9M	+537.6%
Operating Income	-$239M	-$260M	+8.2%
Net Income	-$216M	-$285M	+24.5%